Taking a look at commercial performance of the 10 drugs selected for the initial round of Medicare price negotiation underscores that while they are mega-blockbuster products and large contributors to overall Medicare spending, they are largely mature products approaching the end of their commercial lifecycles.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?